Microcap Ledger PAVmed Inc. $PAVM
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Surgical & Medical Instruments & Apparatus
- Headquarters
- New York, NY
- Fiscal year end
- December 31
- Shares outstanding
- 7,995,918 [10-Q 2026-08-13]
What the company doesAI summary of filing
PAVmed Inc. is a diversified, commercial-stage life sciences company operating in medical devices, diagnostics, and digital health through independently financed subsidiaries. The company generates revenue primarily through Lucid Diagnostics, which commercializes the EsoGuard Esophageal DNA Test and EsoCheck Cell Collection Device for detecting esophageal precancer in at-risk patients, with the test currently reimbursed by commercial insurers and the Veterans Affairs system. Veris Health, a majority-owned subsidiary, offers the Veris Cancer Care Platform, a digital health solution for oncology care monitoring that operates on a software-as-a-service recurring revenue model through partnerships with healthcare institutions. PAVmed is also developing a medical device portfolio including the PortIO implantable intraosseous vascular access device and recently licensed endoscopic imaging technology from Duke University. [10-K 2026-03-27]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $55.0K | −$5.44M | −$5.28M | $3.78M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | $71.0K | −$3.77M | −$5.21M | $1.54M | [10-K 2026-03-27] |
| FY ended Dec 2024 | $3.00M | $31.97M | −$33.55M | $1.19M | [10-K 2025-03-24] |
- Quarterly cash burn
- −$2.64M
- Cash runway Estimate
- ~4.3 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-03-21 | 9,172,331 | [10-K 2024-03-25] |
| 2024-03-31 | 18,750,845 | [10-Q 2024-05-13] |
| 2024-06-30 | 20,417,277 | [10-Q 2024-08-12] |
| 2024-09-30 | 22,054,407 | [10-Q 2024-11-14] |
| 2024-12-31 | 28,310,581 | [10-K 2025-03-24] |
| 2026-03-27 | 6,383,089 | [10-K 2026-03-27] |
| 2026-05-12 | 7,272,739 | [10-Q 2026-05-14] |
| 2026-08-13 | 7,995,918 | [10-Q 2026-08-13] |
- Shelf registration
- S-3 filed 2026-04-21; declared effective 2026-04-29 [S-3 2026-04-21]
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-01-24. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-01-24 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-01-24] |
| 2025-01-21 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-01-21] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-04-02 | Lee Victoria Tou-Ho | grant | 70,000 | — | [4 2026-04-13] |
| 2026-04-02 | Aklog Lishan | grant | 350,000 | — | [4 2026-04-03] |
| 2026-04-02 | Mcgrath Dennis M | grant | 180,000 | — | [4 2026-04-03] |
| 2026-04-02 | Glennon Michael J | grant | 13,930 | — | [4 2026-04-03] |
| 2026-04-02 | Baxter Timothy E | grant | 13,930 | — | [4 2026-04-03] |
| 2026-04-02 | White Debra | grant | 13,930 | — | [4 2026-04-03] |
| 2026-04-02 | Sparks Ronald M | grant | 13,930 | — | [4 2026-04-03] |
| 2026-04-02 | Agrawal Sundeep | grant | 13,930 | — | [4 2026-04-03] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-10 | 8-K | Material agreement entered |
| 2026-09-10 | 424B5 | Prospectus or prospectus supplement |
| 2026-08-14 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-08-13 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-06-24 | 8-K | Director or officer change; Shareholder vote results |
| 2026-05-15 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-05-15 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-05-14 | 10-Q | Quarterly report |
| 2026-05-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-05-11 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-04-30 | DEF 14A | Proxy statement |
Alerts for $PAVM
Email me when PAVmed Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.